Journal of Cell Science and Mutations

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +44-1518-081136

Short Communication - Journal of Cell Science and Mutations (2022) Volume 6, Issue 6

Epithelial-to-mesenchymal transition is promoted by Mnt.

Farlane Mac*

Department of Dentistry-Biomaterials, Institute for Molecular Life Sciences, Radboud University Medical Center, Netherlands

*Corresponding Author:
Farlane Mac
Department of Dentistry-Biomaterials
Institute for Molecular Life Sciences
Radboud University Medical Center, Netherlands

Received: 26-Oct-2022, Manuscript No. AAACSM-22-80460; Editor assigned: 28-Oct-2022, PreQC No. AAACSM-22-80460(PQ); Reviewed: 11-Nov-2022, QC No. AAACSM-22-80460; Revised: 17-Nov-2022, Manuscript No. AAACSM-22-80460(R); Published: 24-Nov-2022, DOI:10.35841/aaacsm-6.6.128

Citation: Mac F. Epithelial-to-mesenchymal transition is promoted by Mnt. J Cell Sci Mut. 2022;6(6):128

Visit for more related articles at Journal of Cell Science and Mutations


When a tumour develops metastatic spread, the survival indices in epithelial neoplasms, like laryngeal carcinoma, rapidly decline. Epithelial-to-mesenchymal transition (EMT), a molecular phenomenon that typically manifests during embryogenesis, is reactivated at the initial stage of metastasis when tumour cells invade the nearby stroma. The hallmarks of this phenomenon include tumour cells losing their epithelial characteristics and acquiring mesenchymal characteristics that increase their ability to migrate. Complex molecular pathways that control the expression of key molecules influencing the tumor's potential for metastasis mediate Loss of adhesion, cytoskeleton remodelling, evasion of immune surveillance and apoptosis, upregulation of metalloproteinases, neovascularization, acquisition of stem-cell characteristics, and activation of tumour stroma are some of the effects of EMT theory apply to laryngeal carcinoma, a tumour with significant morbidity and mortality.


Embryogenesis, Malignant cells, Neovascularization.


The epithelial-to-mesenchymal transition (EMT) a cellbiological programme is crucial to both development and the development of cancer. This programme can cause fully epithelial cells to enter a series of phenotypic states arranged along the epithelial-mesenchymal phenotypic axis, depending on the contextual signals and intracellular gene circuits of a specific cell. These cell states contribute to cancer metastasis and relapse by exhibiting distinctive cellular traits like stemness, invasiveness, drug resistance and the capacity to form metastases at distant organs. The molecular and biochemical mechanisms that cause cells to enter different states along the epithelial-mesenchymal phenotypic spectrum are still not well understood [1].

Novel therapies targeting this cellular programme may help in the treatment of high-grade malignancies if our understanding of the dynamic and plastic nature of the EMT programme is improved. Metastasis, cancer, epithelial-to-mesenchymal transition, and cancer stem cells EMT: A programme of trans differentiation that occurs naturally. EMT programme fundamentals a cell-biological programme known as the epithelial-to-mesenchymal transition (EMT) happens in a variety of tissue types and developmental stages naturally. The EMT programme, as its name suggests, transforms epithelial cells into cells that have advanced into more mesenchymal cell states, which are arranged along an axis of epithelial (E) versus mesenchymal (M). This programme generates cells that enter into a series of intermediate phenotypic states arrayed along the E-M axis and, when driven to its extreme, transforms a fully epithelial cell into one residing in a fully mesenchymal cell state depending on the contextual signals received by a cell within a tissue and the intracellular gene circuitry of the cell [2,3].

The current strategy for EMT, however, employs a holistic model that takes the acquisition of potentials outside of mesenchymal transition into account. A partial EMT model, which represents the cell plasticity involved in invasion and metastasis, is currently accepted because EMT is invariably associated with a reverse mesenchymal-to-epithelial transition (MET). With the introduction of novel molecular targets with prognostic and therapeutic potential, we identify the cumulative evidence in this review that suggests that various aspects of the EMT theory apply to laryngeal carcinoma, a tumour with significant morbidity and mortality. When epithelial tumours spread to other parts of the body, like laryngeal carcinomas, the morbidity and mortality rate significantly decline. Invasion of tumour cells into their stroma is the first step in the multi-step process of metastasis, which then involves the intravasation of cancer cells into blood and lymph vessels. Malignant cells therefore remain dormant until they discover a favourable microenvironment in distant tissues. Malignant cells begin to migrate at that point [4].

Advanced staging and decreased differentiation in clinical samples of laryngeal carcinoma examined by immunohistochemistry are correlated with down regulation of E-cadherin, nuclear translocation of -catenin, and expression of the transcription factors Snail, Slug, and ZEB2. In laryngeal tissue samples, co-expression of E-cadherin and -catenin is correlated with clinicopathological outcomes like lymph node metastasis and overall patient survival. Laryngeal carcinoma cell lines also exhibit a cadherin switch, with N-cadherin taking the place of E-cadherin. In laryngeal carcinoma cell lines, the Twist transcription factor controls the expression of N-cadherin. Another investigation using Hep-2 cell lines revealed that Snail knockdown can prevent EMT [5].


On the other hand, certain molecular pathways that are activated during EMT cause tumour cells to enter a state known as autophagy, a catabolic procedure that typically supports cellular homeostasis by removing damaged organelles and molecules. In autophagy linked to cancer, tumour cells deliberately destroy some of their organelles to lower their energy requirements. In this manner, tumour cells can be kept dormant until they discover conditions that will allow them to multiply once more. EMT and autophagy interact in a complicated way; autophagy can either start or stop EMTactivated by signalling pathways associated with EMT, such as hypoxia or TGF-b. MTOR, one of the most significant autophagy regulators, is a downstream effector of the EMT-related PI3K-Akt pathway. The final impact of EMT on autophagy, however, may depend on the type of cell and the stage of tumour development: during the early stages of tumorigenesis autophagy may prevent the EMT process; On the other hand, after EMT, cells may encourage and use autophagy to avoid apoptosis and immune surveillance, increasing their capacity to metastasize.


  1. Chen Z, Fang Z, Ma J. Regulatory mechanisms and clinical significance of vimentin in breast cancer. Biomed Pharm. 2021;133:111068.
  2. Indexed at, Google scholar, Cross ref

  3. Kisoda S, Shao W, Fujiwara N, et al. Prognostic value of partial EMT-related genes in head and neck squamous cell carcinoma by a bioinformatic analysis. Oral Dis. 2020;26(6):1149-56.
  4. Indexed at, Google scholar, Cross ref

  5. Fan L, Wang J, Deng P, et al. Foxhead box D1 promotes the partial epithelial-to-mesenchymal transition of laryngeal squamous cell carcinoma cells via transcriptionally activating the expression of zinc finger protein 532. Bio engineered. 2022;13(2):3057-69.
  6. Indexed at, Google scholar, Cross ref

  7. Aggarwal V, Montoya CA, Donnenberg VS et al. Interplay between tumor microenvironment and partial EMT as the driver of tumor progression. Sci. 2021;24(2):102113.
  8. Indexed at, Google scholar, Cross ref

  9. Vining KH, Mooney DJ. Mechanical forces direct stem cell behaviour in development and regeneration. Nat Rev Mol Cell Biol. 2017;18:728-42.
  10. Indexed at, Google scholar, Cross ref

Get the App